Aura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $23.00.

Several research analysts have issued reports on the stock. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank lifted their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, BTIG Research upped their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. This represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 67,259 shares of company stock valued at $780,699. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds have recently bought and sold shares of the company. Long Focus Capital Management LLC grew its holdings in Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. boosted its position in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after buying an additional 216,266 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Aura Biosciences in the 3rd quarter valued at about $1,037,000. Bank of New York Mellon Corp increased its holdings in Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after acquiring an additional 48,549 shares in the last quarter. Finally, Barclays PLC raised its position in Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Down 5.0 %

Shares of AURA opened at $9.47 on Tuesday. The stock has a 50 day moving average price of $9.82 and a 200 day moving average price of $8.53. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38. The company has a market capitalization of $473.04 million, a price-to-earnings ratio of -5.47 and a beta of 0.33.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, equities analysts anticipate that Aura Biosciences will post -1.7 EPS for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.